CRDF Stock Overview
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Cardiff Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.75 |
| 52 Week High | US$3.56 |
| 52 Week Low | US$1.13 |
| Beta | 1.6 |
| 1 Month Change | 12.90% |
| 3 Month Change | 23.24% |
| 1 Year Change | -45.82% |
| 3 Year Change | -4.37% |
| 5 Year Change | -93.90% |
| Change since IPO | -99.89% |
Recent News & Updates
Recent updates
Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
Sep 14Cardiff Oncology: Down But Not Out
Aug 22Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Jun 20
Cardiff Oncology: Upcoming Readouts And Several Green Lights
Jun 07Cardiff Oncology: Risky Investment
May 19Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance
Mar 01We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Jan 28Cardiff: The Pfizer Interest Is Interesting
Dec 15Circling Back On Cardiff Oncology
Oct 12Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 26Cardiff Oncology: Current Slump Doesn't Look Right
Jun 14Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Apr 29How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?
Feb 28What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?
Jan 24Cardiff Oncology, Inc. (NASDAQ:CRDF) Analysts Are Reducing Their Forecasts For Next Year
Dec 02
Cardiff Oncology: A Breakout Darkhorse In The Booming K-Ras Market
Nov 24Shareholder Returns
| CRDF | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.6% | -0.3% | 1.7% |
| 1Y | -45.8% | 5.3% | -9.1% |
Return vs Industry: CRDF underperformed the US Biotechs industry which returned 5.3% over the past year.
Return vs Market: CRDF underperformed the US Market which returned -9.1% over the past year.
Price Volatility
| CRDF volatility | |
|---|---|
| CRDF Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CRDF is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: CRDF's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 23 | Mark Erlander | https://www.cardiffoncology.com |
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company’s TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer.
Cardiff Oncology, Inc. Fundamentals Summary
| CRDF fundamental statistics | |
|---|---|
| Market Cap | US$78.19m |
| Earnings (TTM) | -US$39.47m |
| Revenue (TTM) | US$391.00k |
200.0x
P/S Ratio-2.0x
P/E RatioIs CRDF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRDF income statement (TTM) | |
|---|---|
| Revenue | US$391.00k |
| Cost of Revenue | US$17.84m |
| Gross Profit | -US$17.44m |
| Other Expenses | US$22.03m |
| Earnings | -US$39.47m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.88 |
| Gross Margin | -4,461.64% |
| Net Profit Margin | -10,095.40% |
| Debt/Equity Ratio | 0% |
How did CRDF perform over the long term?
See historical performance and comparison